The overall research interests in my laboratory focus on understanding the causes and the impacts of aberrant epigenetics, protein kinases, and RNA/DNA N6-Methyladenosine (m6A) in cancer pathogenesis and resistance to therapeutics, including chemotherapies and molecular targeted therapies. We use a multidisciplinary approach with molecular biology, animal modeling and human biospecimens as our cornerstones to identify and validate inhibitory molecules to restore key antineoplastic features of kinase signaling, epigenetic landscapes and m6A methylation in human cancer cells. In the past decade, I have served as PI or Co-I on multiple grants funded by NIH and my own Institutions. I have an excellent record of scholarly publications in top-ranking peer-reviewed journals. I am corresponding author for publications in Cancer Cell, Cell Research, Nature Communications, Blood, Leukemia, Cancer Research, Clinical Cancer Research, Oncogene, Cell Death and Disease, Journal of Biological Chemistry, and so on. I am co-author for publications in Cell, Cancer Cell, Cell Metabolism, Nature Genetics, Immunity, The Journal of Clinical Investigation, The Journal of Clinical Oncology, and many others. I have established myself as a leader in the fields of cancer epigenetics and experimental therapeutics.